Gilead Sciences Inc. (NASDAQ: GILD) has agreed to purchase Repare Therapeutics Inc.'s (NASDAQ: RPTX) polymerase theta (Polθ) ATPase inhibitor, RP-3467. The drug is currently in the POLAR Phase 1 trial, studying its safety, pharmacokinetics, pharmacodynamics, and preliminary activity either alone or combined with olaparib in adults with various cancers. Gilead emphasized their expertise in oncology research and development coupled with RP-3467's potential as a top Polθ ATPase inhibitor. Detailed information can be found on Benzinga.com.